The Motley Fool reports that biotech stocks surged in 2025, driven by FDA approvals and a doubling of longevity investment to $8.49 billion.

The iShares Biotechnology ETF is up over 32% in six months on rate cut expectations and potential sector rotation. The State Street SPDR S&P Biotech ETF has surged 45% in six months but remains 27% ...

Biotech and drug-innovation themes continue to dominate markets—from AI-driven drug discovery to blockbuster obesity treatments—and a new ETF filing suggests asset managers want a piece of that ...

The State Street SPDR S&P Biotech ETF (XBI) was launched on January 31, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of ...

Fri, January 16, 2026 at 1:06 PM UTC Triple-leveraged ETFs aren't for everyone, but if you believe biotech is about to break out, Direxion Daily S&P Biotech Bull 3X Shares (NASDAQ:LABU) offers the ...

VanEck Biotech ETF receives a Hold rating due to mixed outlooks among its top holdings and unattractive valuation metrics. BBH's heavy concentration in Amgen, Gilead Sciences, and Vertex ...

There is no denying that the pandemic has opened up investment opportunities in the biotech sector by triggering a race to introduce vaccines and treatment options. Moreover, increasing mergers and ...

Kentucky-based Aristides Capital sold 28,467 shares of IBB in the third quarter. The shares were worth an estimated $3.60 million. The move marked a full exit from the position, which was previously ...